Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AssigneeBoehringer Ingelheim International GmbH
InventorsKlaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
Claims6
A method for improving glycemic control compared with placebo in a type 2 diabetes patient, said method comprising administering linagliptin 5 mg qd for at least 24 weeks, as monotherapy wherein the patient is a drug naïve type 2 diabetes patient, or as add-on combination therapy with metformin wherein the patient is a type 2 diabetes patient with insufficient glycemic control on metformin, or
- as add-on combination therapy with metformin and a sulfonylurea wherein the patient is a type 2 diabetes patient with insufficient glycemic control on the combination of metformin and a sulfonylurea.
Dependencies are inferred from the claim text.